For Providers

How to Refer a Patient

We welcome referrals from psychiatric providers, therapists, primary care providers, and other medical professionals.

Please fax referrals to: 423-523-0848 

We aim to respond to referrals within 3 business days.

Indications/Contraindications for Spravato®

Spravato® (esketamine) is FDA-approved for adults with treatment-resistant depression. Indications include:

  • Diagnosis of Major Depressive Disorder (MDD)

  • Inadequate response to at least two different antidepressants

  • Ability to safely attend in-office monitoring appointments twice per week initially

Spravato may not be appropriate for patients with:

  • Aneurysmal vascular disease

  • History of intracerebral hemorrhage

  • Unmanaged substance use disorder

  • Active psychosis

  • Unstable cardiovascular conditions

If you’re unsure, feel free to consult with us—we’re happy to collaborate on clinical appropriateness.

Accepted Insurances

We are currently in the process of credentialing with most major insurance panels and will need to update the list as it happens. 

We are currently accepting self-pay patients until credentialing is complete. The applications can take up to 120 days.

Credentialing applications are in for BCBS, Cigna/Evernorth, UHC/Optum, Humana, Wellpoint, Ambetter, and Blucare.